A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06317285 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

158

Enrollment

INDUSTRY

Sponsor class

Stopped The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: GSK3915393
DRUG: Placebo

Sponsor

GlaxoSmithKline